Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation T cell-engaging bispecific antibodies for the treatment of solid tumors, ...
A team of researchers from the Keck School of Medicine of USC has unlocked the details of a cellular pathway that triggers ...
IgGenix, Inc., a clinical-stage biotechnology company pioneering innovative treatments for immune-mediated diseases, today ...
It is closely associated with tumorigenesis and drug resistance, making it a potential target for oncology drug development. To date, no ROR1-targeting drugs have been marketed. BR111 utilizes ...
In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve ...
Mozart Therapeutics, the leading developer of CD8 Treg network modulators in autoimmune disease, announces the presentation ...
Cambridge, Massachusetts Thursday, February 6, 2025, 13:00 Hrs [IST] ...
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the 'Company'), a global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback